Skip to content
    MRVI
    Earnings call· Jun 2026(Q2 FY26)

    MARAVAI LIFESCIENCES HOLDINGS Q2 FY26 earnings call MRVI

    Aug 6, 2026 Source

    Executive summary

    Maravai LifeSciences Q2 FY26 — Strong Execution Drives Profitability and Balance Sheet Improvement

    Maravai LifeSciences delivered a strong second quarter, marked by significant profitability improvements and a strengthened balance sheet. The company's strategic focus on innovation, commercial execution, and operational excellence drove robust growth in high-margin mRNA segments, particularly GMP consumables and discovery. While full-year revenue guidance was maintained due to the inherent lumpiness of large orders, management expressed confidence in the underlying business momentum and long-term growth trajectory as customer programs advance.

    Highlights

    6

    • Revenue grew 9% year-over-year to $51.4 million, driven by strong demand for GMP consumables and discovery mRNA.

    • Adjusted gross margin expanded over 1,600 basis points year-over-year to 58.9%.

    • Adjusted EBITDA improved by $19.1 million year-over-year to $8.7 million, exceeding expectations.

    • Debt refinanced, reducing borrowings to approximately $150 million and extending maturities to 2032.

    • TriLink's GMP consumables grew 55% year-over-year, with no COVID-related revenue.

    • Added 67 new customers in Q2, a record for new customer acquisitions, largely driven by e-commerce.

    Concerns

    2

    • CDMO business was down year-over-year, in line with expectations due to timing of customer programs.

    • Revenue guidance for FY26 maintained at $205 million to $215 million, reflecting prudence due to lumpiness of large orders and CDMO projects.

    Guidance & targets

    8
    CategoryTargetConfidence
    Full-year 2026 Revenue
    $205 million to $215 million
    high materiality
    High
    Full-year 2026 TriLink Revenue Growth
    high teens
    medium materiality
    High
    Full-year 2026 Cygnus Revenue Growth
    low to mid-single-digit growth
    medium materiality
    High
    Full-year 2026 Adjusted EBITDA
    $33 million to $35 million
    high materiality
    High
    Full-year 2026 Adjusted Gross Margin Improvement
    greater than 1,400 basis points
    medium materiality
    High
    GMP ModTail Orders
    expected in 2027
    medium materiality
    High
    Commercial Program Launches (non-COVID)
    expected to begin around 2028 and 2029
    high materiality
    Medium
    TriLink mRNA Business Long-term Growth
    high single-digit to low double-digit rates
    high materiality
    High

    Segment performance

    2
    SegmentRevenueYoYQoQMargin
    TriLink
    Driven by strong demand for GMP consumables and continued strength in discovery mRNA. CDMO was down year-over-year due to timing of customer programs. Specialty chemistry was steady. Benefited from high-margin GMP product mix and improved operating leverage.
    mRNA revenue growth: 17% YoY (Discovery mRNA)GMP consumables growth: 55% YoYCDMO revenue: <5% of expected 2026 revenueSpecialty chemistry revenue: >20% of expected 2026 revenueAdjusted EBITDA improvement: $14.2 million YoY
    		$34.4 million12%—$7 million adjusted EBITDA
    Cygnus
    Delivered another solid quarter, marking its fifth consecutive quarter of growth. Saw steady demand for HCP and ELISA kits and strength in China due to distributor ordering timing.
    HCP and ELISA kits demand: steadyChina revenue strength: due to distributor ordering timing
    		$17 million3%—$11.4 million adjusted EBITDA

    Operational metrics

    18
    Total Revenue
    $51.4 million9% year-over-year growth
    Q2 FY26
    Adjusted Gross Margin
    58.9%expanded more than 1,600 basis points year-over-year
    Q2 FY26

    Reflects higher revenue, favorable product mix and benefits of operating model.

    Adjusted EBITDA
    $8.7 millionimproved by $19.1 million year-over-year
    Q2 FY26

    Exceeded expectations, driven by stronger revenue, favorable mix toward higher-margin GMP and mRNA discovery, and continued OpEx discipline.

    Adjusted EPS
    loss of $0.02compared to a loss of $0.08 per share last year
    Q2 FY26
    Cash and Equivalents
    $70.1 million
    Q2 FY26
    Total Debt
    $147.1 millionreduced from approximately $150 million
    Q2 FY26

    Refinanced in early June, extending maturities to 2032.

    Depreciation and Amortization
    $11.8 million
    Q2 FY26
    Net Interest Expense
    $3.7 million
    Q2 FY26
    Stock-Based Compensation
    $10.2 million
    Q2 FY26
    Corporate Expenses Impacting Adjusted EBITDA
    $9.7 million
    Q2 FY26

    Includes HR, finance, legal, IT and public company costs.

    New Customer Acquisitions
    67record quarter
    Q2 FY26

    A record quarter for new customer acquisitions, largely driven by e-commerce.

    ModTail Active Customers
    more than 125since commercial launch 1 year ago
    Q2 FY26

    Includes many of the world's leading pharmaceutical companies, with adoption accelerating through new accounts, repeat orders, and broader use.

    COVID GMP-related Revenue
    $0
    Q2 FY26

    No COVID GMP-related revenue in Q2, compared to $14.3 million in Q1.

    GMP Customers (Clinical Trials)
    64 added in Q2
    YTD FY26

    Total of 6 customers have transitioned to GMP YTD, towards a target of 9 for the full year.

    Base Business Revenue
    a little over $100 million
    H1 FY26

    Refers to the base business excluding large, lumpy orders.

    Revenue by Customer Type
    30% biopharma, 35% life sciences and diagnostics, 5% academia, 7% CRO/CMO/CDMO, 23% distributors
    Q2 FY26

    Well diversified across end markets.

    Revenue by Geography
    62% North America, 20% EMEA, 11% Asia Pacific (excluding China), 7% China
    Q2 FY26
    TriLink mRNA Business % of Revenue
    approximately 35%
    expected FY26

    Represents approximately 35% of expected 2026 revenue, excluding COVID CleanCap.

    Industry KPIs

    3
    MetricValueDetails
    Revenue EPS guidanceFY26 Revenue: $205M-$215M; FY26 Adjusted EBITDA: $33M-$35MUSD
    China revenue exposure7%%
    Segment organic revenue growthTriLink: 12%; Cygnus: 3%%

    Product announcements

    3
    ProductTypeDetails
    GMP-grade enzyme portfoliolaunch
    GMP-grade ModTaillaunch
    Residual Prism A Mix-N-Go kitlaunch

    Risks & headwinds

    2
    Variability in timing of large program-driven ordersQuarter-to-quarter

    Individual orders can be large (multi-million dollar type) and their timing can vary meaningfully quarter-to-quarter.

    Mitigation: Prudent revenue guidance; practice not to assume orders until confirmed.

    Project-based and variable nature of CDMO businessQuarter-to-quarter

    CDMO was down year-over-year and in line with expectations based on the timing of customer programs.

    Mitigation: Acknowledged as inherent to the business; managed through selective customer engagement.

    What to watch in Q3 FY26

    4

    GMP Customer Conversions

    next quarter (Q3 FY26) and Q4 FY26
    Current6 YTD (4 in Q2)
    Target9 for FY26

    Why it matters

    Indicates progress of customer programs from discovery to clinical development, a key driver of future revenue.

    So we're at 6 now. We added 4 in the second quarter. And so yes, we see the 9 for -- the 3 remainder for the year that should be changed.

    Q&A highlights

    6

    Inquired about the prudence behind maintaining revenue guidance despite strong H1, noting the implied step-down in H2, and asked about ModTail/Enzyme contributions.

    Management confirmed the prudence is due to the lumpiness of large CDMO and GMP orders, which are program-driven and not assumed until confirmed. Q3 is seasonally lower. GMP ModTail orders are expected in 2027, while the first enzyme order has shipped.

    “Our practice is not to assume those orders until we can see them.”

    asked by Matthew Stanton · answered by Rajesh Asarpota

    2 min read5 chapters

    Detailed Narrative

    01

    Strategic Priorities and Execution

    Maravai continued to execute against its three strategic priorities: innovation, commercial execution, and operational excellence. Innovation efforts included the launch of a new GMP-grade enzyme portfolio and a new residual Prism A Mix-N-Go kit, alongside expanding mass spec analytical services. Commercial momentum was strong, evidenced by 67 new customer acquisitions in Q2 and record e-commerce revenue. Operational excellence was driven by completed restructuring actions and debt refinancing, fundamentally resetting the cost structure and building an operating model designed for scale.

    02

    TriLink Business Model Breakdown

    To provide greater investor visibility, TriLink's business is now viewed through three distinct market categories: mRNA, CDMO, and specialty chemistry. mRNA is the largest and most strategic, spanning discovery (17% YoY growth in Q2), GMP consumables (55% YoY growth in Q2), and future commercial programs (expected 2028-2029). CDMO, representing less than 5% of FY26 revenue, serves strategic cell and gene therapy customers. Specialty chemistry, over 20% of FY26 revenue, is a stable research tools business with attractive profitability.

    03

    Balance Sheet and Financial Flexibility

    The company significantly strengthened its balance sheet by refinancing debt in June, reducing borrowings to approximately $150 million and extending maturities to 2032. This action, combined with improving profitability, positions Maravai with enhanced liquidity and financial flexibility, supporting future growth initiatives and long-term stability.

    04

    E-commerce Platform Driving Customer Growth

    Maravai's e-commerce platform delivered record quarterly revenue and was a primary driver for the record 67 new customer acquisitions in Q2. This digital strategy is improving ordering automation, data-driven customer engagement, and predictive analytics, particularly in the smaller discovery research segment, contributing to a strong rebound in basic research markets.

    05

    Advancement of GMP Customer Programs

    Maravai reported adding 4 new GMP customers in Q2, bringing the total to 6 conversions year-to-date against an annual target of 9. This progress highlights the successful advancement of customer programs from discovery into clinical development, leveraging TriLink's infrastructure and expanding product offerings like GMP CleanCap and soon GMP ModTail.

    AI-generated summary of the company’s earnings call. Not investment advice.